MedTrace Logo

Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve

NCT02268032 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2019-05-29

No results posted yet for this study

Summary

This study was conducted to evaluate the effect of a continuous administration of dehydroepiandrosterone (DHEA) or other androgenic agents on ovarian reserve markers in women with diminished ovarian reserve (ROD), such as antral follicle count (AFC) and anti-Müllerian hormone (AMH) concentrations.

Conditions

  • Healthy Women
  • Infertility, Female

Interventions

DRUG

DHEA

DHEA 2.2 g in vaginal ring

DRUG

Another Androgenic Agent (VRaA)

Testosterone 35 mg in vaginal ring

DRUG

Fixed combination of 2 androgenic agents (VR2A)

DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring

Sponsors & Collaborators

  • Laboratorios Andromaco S.A.

    lead INDUSTRY

Principal Investigators

  • Grünenthal Study Director · Grünenthal GmbH

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
38 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-15
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02268032 on ClinicalTrials.gov